Company intelligence / Profile preview

iosBio

Burgess Hill / Haywards Heath, West Sussex, United Kingdomiosbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

iosBio’s lead program is an oral Epstein-Barr virus vaccine with preclinical data showing robust mucosal and systemic immunity. The company’s oral COVID‑19 vaccine has entered clinical trials. Their proprietary OraPro platform enables thermostable oral delivery of vaccines as tablets or capsules that do not require cold chain logistics and can be self-administered. Additional programs include an oral influenza vaccine in preclinical studies (“FluVid”) and several others in discovery.

Therapeutic areas: Infectious Diseases
Modalities: Oral vaccines (non-replicating viral vector vaccines)biopharmaceuticals
Industry: Biotech

Drug pipeline

7 assets

iosBio oral influenza vaccine

Approved

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on iosBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iosBio.

Explore the full profile